More

    WHO recommends two new drugs to treat patients with COVID-19

    HealthCOVID-19WHO recommends two new drugs to treat patients with...
    - Advertisment -

    WHO recommends two new drugs to treat patients with COVID-19

    A guideline development group of international experts have made the recommendation based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19 infection.

    The World Health Organisation has strongly recommended the use of the drug baricitinib (a drug used to treat rheumatoid arthritis) for patients with severe or critical COVID-19 in combination with corticosteroids. This recommendation by a WHO Guideline Development Group of international experts in has been reported in The BMJ today.

    Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation, with no observed increase in adverse effects.

    The WHO experts note that baricitinib has similar effects to other arthritis drugs called interleukin-6 (IL-6) inhibitors so, when both are available, they suggest choosing one based on cost, availability, and clinician experience. It is not recommended to use both drugs at the same time.

    - Advertisement -

    However, the experts advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical COVID-19 because low certainty evidence from small trials failed to show benefit and suggests a possible increase in serious side effects with tofacitinib.

    In the same guideline update, WHO also makes a conditional recommendation for the use of the monoclonal antibody sotrovimab in patients with non-severe COVID-19, but only in those at highest risk of hospitalisation, reflecting trivial benefits in those at lower risk.

    A similar recommendation has been made by WHO for another monoclonal antibody drug (casirivimab-imdevimab). The experts also note that there were insufficient data to recommend one monoclonal antibody treatment over another – and they acknowledge that their effectiveness against new variants like omicron is still uncertain.

    As such, they say guidelines for monoclonal antibodies will be updated when additional data become available.

    Living guidelines

    Today’s recommendations are based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19 infection.

    They are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide trustworthy guidance on the management of COVID-19 and help doctors make better decisions with their patients.

    Living guidelines are useful in fast moving research areas like COVID-19 because they allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.

    To make their recommendations, the panel considered a combination of evidence assessing relative benefits and harms, values and preferences, and feasibility issues.

    Today’s guidance adds to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical COVID-19; conditional recommendations for the use of casirivimab-imdevimab (another monoclonal antibody treatment) in selected patients; and against the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with covid-19 regardless of disease severity.

     

    Image: Illustration of the Novel Coronavirus, created at the Centers for Disease Control and Prevention (CDC).

    - Advertisement -

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    Latest news

    Crows Outpace Humans and Monkeys in Split-Second Decision-Making, Study Reveals

    Future studies will investigate whether crows maintain this twofold speed advantage when making non-visual decisions – such as evaluating auditory cues, weighing delayed rewards, or solving multi-step social problems.

    India’s Judges, Policymakers and Activists Confront Escalating Youth Mental Health Crisis

    As South Asian nations grapple with the lingering social fallout of the pandemic, participants concluded that preventing youth despair requires moving beyond reactive crisis management.

    Greenpeace Urges India to Champion Climate Justice and Make Polluters Pay at COP31

    The organisation suggests that these community representatives should have a designated place within the country's official delegations.

    Study Finds No Teaching Quality Gap Between Reservation and General Category Faculty in Indian Engineering Colleges

    Many countries operate affirmative-action, diversity or preferential-hiring programmes in universities and the public sector.
    - Advertisement -

    India’s Retail Inflation Surges to Two-Year High of 6.09% as Food Costs Breach Central Bank Comfort Zone

    While a single monthly reading above 6 per cent does not constitute a formal policy failure, the persistent upward trajectory since early 2026 leaves monetary authorities with little room to manoeuvre.

    Global Experts Unveil First International Food Pyramid Prioritising Plant Foods and Quality Carbohydrates

    The authors stress that individual knowledge alone is insufficient. Food environments – marketing, pricing, availability and access – must support healthier choices.

    Must read

    Crows Outpace Humans and Monkeys in Split-Second Decision-Making, Study Reveals

    Future studies will investigate whether crows maintain this twofold speed advantage when making non-visual decisions – such as evaluating auditory cues, weighing delayed rewards, or solving multi-step social problems.

    India’s Judges, Policymakers and Activists Confront Escalating Youth Mental Health Crisis

    As South Asian nations grapple with the lingering social fallout of the pandemic, participants concluded that preventing youth despair requires moving beyond reactive crisis management.
    - Advertisement -

    More from the sectionRELATED
    Recommended to you